Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.6

Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3.1 to $2.6.
byBenzinga Newsdesk
March 14, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3.1 to $2.6.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts